A Phase II Study of ¹⁷⁷Lu–Lilotomab Satetraxetan, a CD37 Antibody–Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients

<b>Background</b>: CD37, an antigen highly expressed in B-cell malignancies, served as the target in the LYMRIT-37-01 Part B (PARADIGME) and Part C studies employing a single intravenous injection of the radioimmunoconjugate ¹⁷⁷Lu–lilotomab satetraxetan (Betalutin^®). <b>Methods...

Полное описание

Библиографические подробности

Главные авторы:	Roy H. Larsen, Arne Kolstad, Alexander Fosså, Ada Repetto-Llamazares, Knut T. Smerud, Timothy Illidge, Øyvind S. Bruland
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2026-02-01
Серии:	Pharmaceuticals
Предметы:	CD37 single-dose radioimmunotherapy follicular lymphoma Phase IIB
Online-ссылка:	https://www.mdpi.com/1424-8247/19/2/250
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!